Evidence map›Paper›PMID 39012547›Full record

ArticleActa neuropathologica2024

Anti-Ku + myositis: an acquired inflammatory protein-aggregate myopathy.

Marie-Therese Holzer, Akinori Uruha, Andreas Roos, Andreas Hentschel, Anne Schänzer, Joachim Weis, Kristl G Claeys, Benedikt Schoser, Federica Montagnese, Hans-Hilmar Goebel and 10 more

Abstract read
In one paragraph

Article in Acta neuropathologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Marie-Therese HolzerDivision of Rheumatology and Systemic Inflammatory Diseases, III, Department of Medicine, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany. m.holzer@uke.de.ORCID 0000-0002-2064-6728
Akinori UruhaDepartment of Neuropathology, Charité. Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Andreas RoosDepartment of Neuropediatrics, Developmental Neurology and Social Pediatrics, Centre for Neuromuscular Disorders in Children, University Children's Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Andreas HentschelLeibniz-Institut für Analytische Wissenschaften -ISAS- E.V., Dortmund, Germany.
Anne SchänzerInstitute of Neuropathology, Justus-Liebig-University, Gießen, Germany.
Joachim WeisMedical Faculty, Institute of Neuropathology, RWTH Aachen University, Aachen, Germany.
Kristl G ClaeysDepartment of Neurology, University Hospitals Leuven, Leuven, Belgium.
Benedikt SchoserDepartment of Neurology, Friedrich-Baur-Institute, Ludwig-Maximilians-University, Munich, Germany.
Federica MontagneseDepartment of Neurology, Friedrich-Baur-Institute, Ludwig-Maximilians-University, Munich, Germany.
Hans-Hilmar GoebelDepartment of Neuropathology, Charité. Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Melanie HuberDepartment for Rheumatology, Campus Kerckhoff of Justus-Liebig University Gießen, Bad Nauheim, Germany.
Sarah Léonard-LouisReference Center of Neuromuscular Pathology Paris-Est, Pitié-Salpêtrière University Hospital, Paris, France.
Ina KötterDivision of Rheumatology and Systemic Inflammatory Diseases, III, Department of Medicine, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany.
Nathalie StreichenbergerNeuropathologie, Groupement Hospitalier Est, Hospices Civils de Lyon, Université Claude Bernard Lyon 1, Institut NeuroMyogène CNRS UMR 5261- INSERM U1315, Lyon, France.
Laure GallayDepartment of Internal Medicine, Edouard Herriot University Hospital, Hospices Civils de Lyon, Lyon, France.
Olivier BenvenisteDepartment of Internal Medicine and Clinical Immunology, Assistance Publique Hôpitaux de Paris, Sorbonne Université, Pitié-Salpêtrière University Hospital, Paris, France.
Udo Schneider *Department of Rheumatology, Charité, Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Corinna Preusse *Department of Neuropathology, Charité. Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Martin Krusche *Division of Rheumatology and Systemic Inflammatory Diseases, III, Department of Medicine, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany.
Werner Stenzel *Department of Neuropathology, Charité. Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

Funding

European Regional Development Fund NMD-GPS
6 · The paper itself

Abstract

Myositis with anti-Ku-autoantibodies is a rare inflammatory myopathy associated with various connective tissue diseases. Histopathological studies have identified inflammatory and necrotizing aspects, but a precise morphological analysis and pathomechanistic disease model are lacking. We therefore aimed to carry out an in-depth morpho-molecular analysis to uncover possible pathomechanisms. Muscle biopsy specimens from 26 patients with anti-Ku-antibodies and unequivocal myositis were analyzed by immunohistochemistry, immunofluorescence, transcriptomics, and proteomics and compared to biopsy specimens of non-disease controls, immune-mediated necrotizing myopathy (IMNM), and inclusion body myositis (IBM). Clinical findings and laboratory parameters were evaluated retrospectively and correlated with morphological and molecular features. Patients were mainly female (92%) with a median age of 56.5 years. Isolated myositis and overlap with systemic sclerosis were reported in 31%, respectively. Isolated myositis presented with higher creatine kinase levels and cardiac involvement (83%), whereas systemic sclerosis-overlap patients often had interstitial lung disease (57%). Histopathology showed a wide spectrum from mild to pronounced myositis with diffuse sarcolemmal MHC-class I (100%) and -II (69%) immunoreactivity, myofiber necrosis (88%), endomysial inflammation (85%), thickened capillaries (84%), and vacuoles (60%). Conspicuous sarcoplasmic protein aggregates were p62, BAG3, myotilin, or immunoproteasomal beta5i-positive. Proteomic and transcriptomic analysis identified prominent up-regulation of autophagy, proteasome, and hnRNP-related cell stress. To conclude, Ku + myositis is morphologically characterized by myofiber necrosis, MHC-class I and II positivity, variable endomysial inflammation, and distinct protein aggregation varying from IBM and IMNM, and it can be placed in the spectrum of scleromyositis and overlap myositis. It features characteristic sarcoplasmic protein aggregation on an acquired basis being functionally associated with altered chaperone, proteasome, and autophagy function indicating that Ku + myositis exhibit aspects of an acquired inflammatory protein-aggregate myopathy.

Indexed as

AutoantibodiesKu AutoantigenMyositisAdultAgedFemaleHumansMaleMiddle AgedMuscle, SkeletalMyositis, Inclusion BodyRetrospective StudiesAutoantibodiesKu AutoantigenXrcc6 protein, humanAutoantibodiesAutophagyConnective tissue diseasesMyositisOverlap syndromeSystemic sclerosis

Identifiers

PMID39012547
PMCPMC11252205

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.